Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 105

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 105
---
 and increasing the potential for breakthrough developments. •Product Portfolio Expansion: The Merger aligns differentiated but synergistic offerings, allowing for enhanced cross -productfunctionality and bundling opportunities, particularly regarding the treatment/cure of diabetes. •Operational Expertise: NLS and Kadimastem leverage specialized knowledge in distinct areas (e.g., manufacturing, commercialization, regulatory processes, R&D) to create a stronger, more agile operational structure. •Go -to-Market& Customer Reach: Combining resources broadens market access, enabling entry into new geographical regions and a more diverse customer base. •Expansion of Market Reach: The Merger allows the combined company to increase market penetration and geographical coverage, creating a stronger competitive presence. Specifically: •Expanded R&D Influence & Industry Presence: While NLS and Kadimastem currently lack established salesforces or distribution channels, the Merger: •Strengthens Scientific Credibility: A larger combined research team with broader expertise enhances reputation within the scientific and investment communities. •Improves Attractiveness for Partnerships: The combined company is more appealing for collaborations with pharma, biotech firms, government agencies, and grant funders. •Increases Visibility in Academic & Regulatory Circles: The Merger can lead to more publications, conference presentations, and regulatory engagement, positioning the combined company as a future market leader. •Attracts More Investors & Funding: A combined pipeline and stronger IP portfolio create a more compelling investment case for investors, as well as non -dilutivegrants. •Accelerates Potential Market Entry: Shared R&D efforts may reduce time -to-market, increasing the likelihood of a successful transition from preclinical to clinical stages. •Strengthened Competitive Position :A combined company can compete more effectively in a crowded or consolidating industry. 8 •Risks •Integration Challenges: Combining two different corporate structures, teams, and technologies may lead to unforeseen difficulties. •Potential Cultural Clashes: Differences in company culture, management style, and corporate values could lead to friction, lower morale, and employee attrition. •Regulatory Scrutiny: Regulatory approvals may delay or complicate the Merger process. Financial Considerations •Advantages •Cost Synergies: Significant cost savings are anticipated by eliminating operational redundancies. •Enhanced Financial Stability: A stronger balance sheet enhances flexibility for investments and market fluctuations. •Risks •High Integration Costs: Upfront costs of merging systems, rebranding, and restructuring may be substantial. •Short -TermProfit